R&D Day Hosted by Foamix Pharmaceuticals (FOMX)

Foamix will review its pre-launch medical affairs and commercial strategies for 2019 in support of the company’s product candidate FMX101, 4% topical minocycline foam for moderate to severe acne, as well as provide an update on new Phase 3 data for the company’s product candidate FMX103, 1.5% topical minocycline foam for papulopustular rosacea.